Mednet Logo
CommunityMedical Oncology

Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?

Efficacy and cardiovascular safety appear similar per the PATCH trial updated at ESMO 2024. How would you counsel patients who decline LHRH agonists?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on

My default form of ADT remains a GnRH agonist or antagonist but estradiol transdermal patches are clearly effective and safe as an alternative option for men who either 1) have significant loss of bone density/osteoporosis, 2) have significant hot flashes with traditional ADT and wish to try an alte...

Join for free or sign in to see the full answer